Covid-19 roundup: EMA starts rolling re­view of Rus­si­a's Sput­nik V; No­vavax says shot is 51% ef­fec­tive against vari­ant in South Africa 

The EMA has start­ed a rolling re­view of Sput­nik V, the Russ­ian vac­cine that holds the du­bi­ous ti­tle of the world’s first reg­is­tered jab for Covid-19.

Sev­en months af­ter the con­tro­ver­sial clear­ance in Rus­sia, Eu­rope’s hu­man med­i­cines com­mit­tee says it’s con­vinced to start look­ing at the ap­pli­ca­tion by da­ta in­di­cat­ing that the ade­n­ovirus-based vac­cine trig­gers the pro­duc­tion of an­ti­bod­ies and im­mune cells against the SARS-CoV-2 coro­n­avirus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.